Leukemia Research
Volume 29, Issue 6 , Pages 599-600 , June 2005

Use of biological response modifiers to enhance the action of Rituximab

Received 7 December 2004 ,Accepted 9 December 2004.

References 

  1. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Clin Rev Oncol Hematol. 2001;40:3
  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235
  3. Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie M, et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Meth. 2001;248:103
  4. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25:158
  5. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and β-glucan in cancer. Immunopharm. 1999;42:61
  6. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 1999;36:929
  7. Irie K, Irie RF, Morton DL. Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science. 1974;186:454
  8. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, et al. β-Glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol. 1999;163:3045
  9. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, et al. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003;63:9023
  10. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173:797
  11. Modak S, Koehne G, Vickers A, O’Reilly RJ, Cheung NV. Rituximab therapy of lymphoma is enhanced by orally administered (1-3),(1-4)-β-d-glucan. Leuk Res. 2005;29:679
  12. Cheung NV, Modak S, Vickers A, Knuckles B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557
  13. Cheung NV, Modak S. Oral (1-3),(1-4)-β-d-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217
  14. Hernandex-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of Rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. 2003;9:5866
  15. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood. 2003;101:1071
  16. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280
  17. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of Rituximab in vivo. J Immunol. 2003;171:1581
  18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443
  19. Ong G, Mattes M. Mouse strains with typical mammalian levels of complement activity. J Immunol Meth. 1989;125:147
  20. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99:754
  21. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arth Rheum. 2003;48:455
  22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to Rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940
  23. Funakoshi S, Longo DL, Murphy WJ. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother. 1996;19:93
  24. Ehlenberger AG, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med. 1977;145:357
  25. Fries LF, Siwik SA, Malbran A, Frank MM. Phagocytosis of target particles bearing C3b–IgG covalent complexes by human monocytes and polymorphonuclear leukocytes. Immunology. 1987;62:45
  26. Zhou M, Todd RF, van de Winkel JGJ, Petty HR. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fcγ receptor III on human neutrophils. J Immunol. 1993;150:3030
  27. Lazar G, Dang W, Vafa O, Karki S, Vielmetter J, Doberstein S, et al. Improving the efficacy of rituxan by rational protein engineering. Blood. 2004;104:394a

PII: S0145-2126(05)00049-4

doi: 10.1016/j.leukres.2004.12.014

Leukemia Research
Volume 29, Issue 6 , Pages 599-600 , June 2005

Article Tools